ChiCTR2600126902 Pemetrexed Dipotassium HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines ChiCTR2600126902—Bevacizumab plus immune checkpoint inhibitor and pemetrexed versus platinum‑based chemotherapy plus immune checkpoint inhibitor and pemetrexed as first‑line treatment for elderly, HIV‑positive, stage IV driver gene‑negative non‑squamous non‑small cell lung cancer: a multicenter, randomized, open‑label, controlled trial—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why ChiCTR2600126902 is a hot trial to watch

HIV Infections is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. ChiCTR2600126902 is notable because it evaluates Pemetrexed Dipotassium in a Phase 2 design while Medical history serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Not reported, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 34 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Secondary: Medical history (Baseline)
• Secondary: Concomitant medications (including WBC/platelet growth factors, etc.) (Treatment Period and Single?Agent Maintenance Period)
• Secondary: 12?lead electrocardiogram (ECG) (Baseline，follow?up time)
• Secondary: Hematology (complete blood count: WBC, RBC, Hb, PLT, neutrophils, etc.) (Baseline Period, Treatment Period, Single?Agent Maintenance Period, and Follow?up Period)
• Secondary: Serum biochemistry (liver/kidney function, electrolytes, glucose, lipids, LDH, etc.) (Baseline Period, Treatment Period, Single?Agent Maintenance Period, and Follow?up Period)

Benchmark readouts in the surrounding field

• Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial (Phase 3): AE(serious) = 4.0 %
• Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women (Phase 2): Concentrations of Tenofovir Disphosphate (TFV-DP) Measured at Eight Weeks in Dried Blood Spots (DBS)(Median) = 359 fmol/punch (Inter-Quartile Range, 266 - 464); Concentrations of Tenofovir Disphosphate (TFV-DP) Measured at Eight Weeks in Dried Blood Spots (DBS)(Median) = 798.9 fmol/punch (Inter-Quartile Range, 767.3 - 947.1)
• Efavirenz 400 mg vs. 600 mg Combined with Lamivudine and Tenofovir in Treatment-Naïve HIV-Infected Patients in China: A Randomized, Multi-Centered, Controlled Trial (Phase 3): Virological suppression(72-week) = 84.1 % ; Virological suppression(72-week) = 86.5 %

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Pemetrexed Dipotassium (Approved; DHFR x GART x TYMS); Bevacizumab (Approved; VEGF-A)

Company & Deal Intelligence context: Nanfang Hospital — China — http://www.nfyy.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

ChiCTR2600126902 is a focused lens on HIV Infections development. Its value will be determined by whether Pemetrexed Dipotassium can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.